Cerus Corporation (CERS) : Rail-splitter Capital Management reduced its stake in Cerus Corporation by 33.36% during the most recent quarter end. The investment management company now holds a total of 427,558 shares of Cerus Corporation which is valued at $3,065,591 after selling 213,999 shares in Cerus Corporation , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Cerus Corporation makes up approximately 0.71% of Rail-splitter Capital Management’s portfolio.
Other Hedge Funds, Including , Spot Trading L.l.c reduced its stake in CERS by selling 12,814 shares or 36.77% in the most recent quarter. The Hedge Fund company now holds 22,039 shares of CERS which is valued at $158,020. Cerus Corporation makes up approx 0.02% of Spot Trading L.l.c’s portfolio.California State Teachers Retirement System boosted its stake in CERS in the latest quarter, The investment management firm added 9,800 additional shares and now holds a total of 211,846 shares of Cerus Corporation which is valued at $1,518,936. Tradewinds Capital Management sold out all of its stake in CERS during the most recent quarter. The investment firm sold 1,000 shares of CERS which is valued $7,390.Creative Planning boosted its stake in CERS in the latest quarter, The investment management firm added 2,000 additional shares and now holds a total of 10,278 shares of Cerus Corporation which is valued at $64,340.Berson Corrado Investment Advisors reduced its stake in CERS by selling 19,250 shares or 50.39% in the most recent quarter. The Hedge Fund company now holds 18,950 shares of CERS which is valued at $122,228. Cerus Corporation makes up approx 0.05% of Berson Corrado Investment Advisors’s portfolio.
Cerus Corporation closed down -0.42 points or -5.75% at $6.88 with 20,60,194 shares getting traded on Monday. Post opening the session at $7.4, the shares hit an intraday low of $6.82 and an intraday high of $7.479 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Cerus Corporation reported $-0.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.17. The company had revenue of $9.25 million for the quarter, compared to analysts expectations of $8.79 million. The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Many Wall Street Analysts have commented on Cerus Corporation. Cantor Fitzgerald Resumed Cerus Corporation on Jul 7, 2016 to “Buy”, Price Target of the shares are set at $9.
Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens such as viruses including HIV West Nile SARS hepatitis B and C; bacteria and parasites as well as potentially harmful white blood cells while preserving the therapeutic properties of platelet plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries including the United States certain countries in Europe The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.